Comparison of amphotericin b with fluconazole in the treatment of acute aids-associated cryptococcal meningitis

Michael S. Saag, Gretchen A. Cloud, William E. Dismukes, William G. Powderly, Michael H. Grieco, Patricia K. Sharkey, Sumner E. Thompson, Alan M. Sugar, Carmelita U. Tuazon, John Fremont Fisher, Newton Hyslop, Jeffrey M. Jacobson, Richard Hafner, Patrick Robinson

Research output: Contribution to journalArticle

534 Citations (Scopus)

Abstract

Background: Intravenous amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS). Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease.Methods: In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patients, in all of whom the diagnosis had been confirmed by culture, were randomly assigned in a 2:1 ratio to receive either fluconazole (200 mg per day) or amphotericin B. Treatment was considered successful if the patient had had two consecutive negative cerebrospinal fluid cultures by the end of the 10-week treatment period.Results: Of the 194 eligible patients, 131 received fluconazole and 63 received amphotericin B (mean daily dose, 0.4 mg per kilogram of body weight in patients with successful treatment and 0.5 mg per kilogram in patients with treatment failure; P = 0.34). Treatment was successful in 25 of the 63 amphotericin B recipients (40 percent; 95 percent confidence interval, 26 percent to 53 percent) and in 44 of the 131 fluconazole recipients (34 percent; 95 percent confidence interval, 25 percent to 42 percent) (P = 0.40). There was no significant difference between the groups in overall mortality due to cryptococcosis (amphotericin vs. fluconazole, 9 of 63 [14 percent] vs. 24 of 131 [18 percent]; P = 0.48); however, mortality during the first two weeks of therapy was higher in the fluconazole group (15 percent vs. 8 percent; P = 0.25). The median length of time to the first negative cerebrospinal fluid culture was 42 days (95 percent confidence interval, 28 to 71) in the amphotericin B group and 64 days (95 percent confidence interval, 53 to 67) in the fluconazole group (P = 0.25). Multivariate analyses identified abnormal mental status (lethargy, somnolence, or obtundation) as the most important predictive factor of a high risk of death during therapy (P<0.0001).Conclusions: Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS. Single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure. The optimal therapy for patients at high risk remains to be determined. (N Engl J Med 1992; 326:83–9.).

Original languageEnglish (US)
Pages (from-to)83-89
Number of pages7
JournalNew England Journal of Medicine
Volume326
Issue number2
DOIs
StatePublished - Jan 9 1992

Fingerprint

Cryptococcal Meningitis
Fluconazole
Amphotericin B
Therapeutics
Confidence Intervals
Acquired Immunodeficiency Syndrome
Treatment Failure
Cerebrospinal Fluid
Flucytosine
Cryptococcosis
Lethargy
Triazoles
Mortality
Multicenter Studies
Multivariate Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Saag, M. S., Cloud, G. A., Dismukes, W. E., Powderly, W. G., Grieco, M. H., Sharkey, P. K., ... Robinson, P. (1992). Comparison of amphotericin b with fluconazole in the treatment of acute aids-associated cryptococcal meningitis. New England Journal of Medicine, 326(2), 83-89. https://doi.org/10.1056/NEJM199201093260202

Comparison of amphotericin b with fluconazole in the treatment of acute aids-associated cryptococcal meningitis. / Saag, Michael S.; Cloud, Gretchen A.; Dismukes, William E.; Powderly, William G.; Grieco, Michael H.; Sharkey, Patricia K.; Thompson, Sumner E.; Sugar, Alan M.; Tuazon, Carmelita U.; Fisher, John Fremont; Hyslop, Newton; Jacobson, Jeffrey M.; Hafner, Richard; Robinson, Patrick.

In: New England Journal of Medicine, Vol. 326, No. 2, 09.01.1992, p. 83-89.

Research output: Contribution to journalArticle

Saag, MS, Cloud, GA, Dismukes, WE, Powderly, WG, Grieco, MH, Sharkey, PK, Thompson, SE, Sugar, AM, Tuazon, CU, Fisher, JF, Hyslop, N, Jacobson, JM, Hafner, R & Robinson, P 1992, 'Comparison of amphotericin b with fluconazole in the treatment of acute aids-associated cryptococcal meningitis', New England Journal of Medicine, vol. 326, no. 2, pp. 83-89. https://doi.org/10.1056/NEJM199201093260202
Saag, Michael S. ; Cloud, Gretchen A. ; Dismukes, William E. ; Powderly, William G. ; Grieco, Michael H. ; Sharkey, Patricia K. ; Thompson, Sumner E. ; Sugar, Alan M. ; Tuazon, Carmelita U. ; Fisher, John Fremont ; Hyslop, Newton ; Jacobson, Jeffrey M. ; Hafner, Richard ; Robinson, Patrick. / Comparison of amphotericin b with fluconazole in the treatment of acute aids-associated cryptococcal meningitis. In: New England Journal of Medicine. 1992 ; Vol. 326, No. 2. pp. 83-89.
@article{29ec34558a7f47eabfc42b2f113472c8,
title = "Comparison of amphotericin b with fluconazole in the treatment of acute aids-associated cryptococcal meningitis",
abstract = "Background: Intravenous amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS). Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease.Methods: In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patients, in all of whom the diagnosis had been confirmed by culture, were randomly assigned in a 2:1 ratio to receive either fluconazole (200 mg per day) or amphotericin B. Treatment was considered successful if the patient had had two consecutive negative cerebrospinal fluid cultures by the end of the 10-week treatment period.Results: Of the 194 eligible patients, 131 received fluconazole and 63 received amphotericin B (mean daily dose, 0.4 mg per kilogram of body weight in patients with successful treatment and 0.5 mg per kilogram in patients with treatment failure; P = 0.34). Treatment was successful in 25 of the 63 amphotericin B recipients (40 percent; 95 percent confidence interval, 26 percent to 53 percent) and in 44 of the 131 fluconazole recipients (34 percent; 95 percent confidence interval, 25 percent to 42 percent) (P = 0.40). There was no significant difference between the groups in overall mortality due to cryptococcosis (amphotericin vs. fluconazole, 9 of 63 [14 percent] vs. 24 of 131 [18 percent]; P = 0.48); however, mortality during the first two weeks of therapy was higher in the fluconazole group (15 percent vs. 8 percent; P = 0.25). The median length of time to the first negative cerebrospinal fluid culture was 42 days (95 percent confidence interval, 28 to 71) in the amphotericin B group and 64 days (95 percent confidence interval, 53 to 67) in the fluconazole group (P = 0.25). Multivariate analyses identified abnormal mental status (lethargy, somnolence, or obtundation) as the most important predictive factor of a high risk of death during therapy (P<0.0001).Conclusions: Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS. Single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure. The optimal therapy for patients at high risk remains to be determined. (N Engl J Med 1992; 326:83–9.).",
author = "Saag, {Michael S.} and Cloud, {Gretchen A.} and Dismukes, {William E.} and Powderly, {William G.} and Grieco, {Michael H.} and Sharkey, {Patricia K.} and Thompson, {Sumner E.} and Sugar, {Alan M.} and Tuazon, {Carmelita U.} and Fisher, {John Fremont} and Newton Hyslop and Jacobson, {Jeffrey M.} and Richard Hafner and Patrick Robinson",
year = "1992",
month = "1",
day = "9",
doi = "10.1056/NEJM199201093260202",
language = "English (US)",
volume = "326",
pages = "83--89",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "2",

}

TY - JOUR

T1 - Comparison of amphotericin b with fluconazole in the treatment of acute aids-associated cryptococcal meningitis

AU - Saag, Michael S.

AU - Cloud, Gretchen A.

AU - Dismukes, William E.

AU - Powderly, William G.

AU - Grieco, Michael H.

AU - Sharkey, Patricia K.

AU - Thompson, Sumner E.

AU - Sugar, Alan M.

AU - Tuazon, Carmelita U.

AU - Fisher, John Fremont

AU - Hyslop, Newton

AU - Jacobson, Jeffrey M.

AU - Hafner, Richard

AU - Robinson, Patrick

PY - 1992/1/9

Y1 - 1992/1/9

N2 - Background: Intravenous amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS). Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease.Methods: In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patients, in all of whom the diagnosis had been confirmed by culture, were randomly assigned in a 2:1 ratio to receive either fluconazole (200 mg per day) or amphotericin B. Treatment was considered successful if the patient had had two consecutive negative cerebrospinal fluid cultures by the end of the 10-week treatment period.Results: Of the 194 eligible patients, 131 received fluconazole and 63 received amphotericin B (mean daily dose, 0.4 mg per kilogram of body weight in patients with successful treatment and 0.5 mg per kilogram in patients with treatment failure; P = 0.34). Treatment was successful in 25 of the 63 amphotericin B recipients (40 percent; 95 percent confidence interval, 26 percent to 53 percent) and in 44 of the 131 fluconazole recipients (34 percent; 95 percent confidence interval, 25 percent to 42 percent) (P = 0.40). There was no significant difference between the groups in overall mortality due to cryptococcosis (amphotericin vs. fluconazole, 9 of 63 [14 percent] vs. 24 of 131 [18 percent]; P = 0.48); however, mortality during the first two weeks of therapy was higher in the fluconazole group (15 percent vs. 8 percent; P = 0.25). The median length of time to the first negative cerebrospinal fluid culture was 42 days (95 percent confidence interval, 28 to 71) in the amphotericin B group and 64 days (95 percent confidence interval, 53 to 67) in the fluconazole group (P = 0.25). Multivariate analyses identified abnormal mental status (lethargy, somnolence, or obtundation) as the most important predictive factor of a high risk of death during therapy (P<0.0001).Conclusions: Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS. Single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure. The optimal therapy for patients at high risk remains to be determined. (N Engl J Med 1992; 326:83–9.).

AB - Background: Intravenous amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS). Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease.Methods: In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patients, in all of whom the diagnosis had been confirmed by culture, were randomly assigned in a 2:1 ratio to receive either fluconazole (200 mg per day) or amphotericin B. Treatment was considered successful if the patient had had two consecutive negative cerebrospinal fluid cultures by the end of the 10-week treatment period.Results: Of the 194 eligible patients, 131 received fluconazole and 63 received amphotericin B (mean daily dose, 0.4 mg per kilogram of body weight in patients with successful treatment and 0.5 mg per kilogram in patients with treatment failure; P = 0.34). Treatment was successful in 25 of the 63 amphotericin B recipients (40 percent; 95 percent confidence interval, 26 percent to 53 percent) and in 44 of the 131 fluconazole recipients (34 percent; 95 percent confidence interval, 25 percent to 42 percent) (P = 0.40). There was no significant difference between the groups in overall mortality due to cryptococcosis (amphotericin vs. fluconazole, 9 of 63 [14 percent] vs. 24 of 131 [18 percent]; P = 0.48); however, mortality during the first two weeks of therapy was higher in the fluconazole group (15 percent vs. 8 percent; P = 0.25). The median length of time to the first negative cerebrospinal fluid culture was 42 days (95 percent confidence interval, 28 to 71) in the amphotericin B group and 64 days (95 percent confidence interval, 53 to 67) in the fluconazole group (P = 0.25). Multivariate analyses identified abnormal mental status (lethargy, somnolence, or obtundation) as the most important predictive factor of a high risk of death during therapy (P<0.0001).Conclusions: Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS. Single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure. The optimal therapy for patients at high risk remains to be determined. (N Engl J Med 1992; 326:83–9.).

UR - http://www.scopus.com/inward/record.url?scp=0026320039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026320039&partnerID=8YFLogxK

U2 - 10.1056/NEJM199201093260202

DO - 10.1056/NEJM199201093260202

M3 - Article

C2 - 1727236

AN - SCOPUS:0026320039

VL - 326

SP - 83

EP - 89

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 2

ER -